Emerging research suggest this peptide, a dual stimulator targeting both GLP-1 and GIP , appears to offer a promising development for weight loss . Initial patient trials have shown impressive losses in abdominal tissue, possibly surpassing other weight-loss medications . Despite this, further assessment is necessary to thoroughly assess its long-t